Compare
DiaMedica Therapeutics Inc. vs Q32 Bio Inc. vs AN2 Therapeutics, Inc. vs Lifevantage Corp
| Latest fiscal year | DiaMedica Therapeutics Inc. DMAC | Q32 Bio Inc. QTTB | AN2 Therapeutics, Inc. ANTX | Lifevantage Corp LFVN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | n/a | $53.74M | n/a | $182.59M |
| Revenue growth (YoY) | n/a | n/a | n/a | -20.1% |
| Gross margin | n/a | n/a | n/a | 77.6% |
| Operating margin | n/a | 31.5% | n/a | 3.3% |
| Net margin | n/a | 55.5% | n/a | 2.8% |
| Net income | -$32.77M | $29.82M | -$35.17M | $5.07M |
| EPS (Diluted) | n/a | $2.42 | -$1.16 | $0.40 |
| Operating cash flow | -$29.06M | -$33.54M | -$29.83M | $10.24M |
| Free cash flow | -$29.10M | -$33.54M | n/a | $6.67M |
| Cash & equivalents | $15.65M | $48.30M | $19.94M | n/a |
| Total assets | $61.37M | $61.78M | $61.95M | $62.11M |
| Total liabilities | n/a | $19.76M | $8.89M | $28.52M |
| Shareholders' equity | $56.11M | $42.01M | $53.06M | $33.59M |
| Return on year-end equity | -58.4% | 71.0% | -66.3% | 15.1% |
| Shares outstanding | 53.74M | 12.86M | 27.41M | 12.52M |
Revenue, most recent five fiscal years
| Fiscal year | DiaMedica Therapeutics Inc. | Q32 Bio Inc. | AN2 Therapeutics, Inc. | Lifevantage Corp |
|---|---|---|---|---|
| Latest | $500.0K Ended 2018-12-31 | $53.74M Ended 2025-12-31 | n/a | $182.59M Ended 2026-06-30 |
| 1 year earlier | n/a | $0 Ended 2024-12-31 | n/a | $228.53M Ended 2025-06-30 |
| 2 years earlier | n/a | -$6.65M Ended 2023-12-31 | n/a | $200.16M Ended 2024-06-30 |
| 3 years earlier | n/a | n/a | n/a | $213.40M Ended 2023-06-30 |
| 4 years earlier | n/a | n/a | n/a | $206.36M Ended 2022-06-30 |